Welcome to our dedicated page for Drugs Made In America Acquisition II SEC filings (Ticker: DMIIU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Drugs Made In America Acquisition II Corp. filings document a blank-check issuer's securities, governance and capital structure. The company's Form 8-K reports cover material definitive agreements, financing instruments such as unsecured convertible notes, consulting arrangements for financial and accounting officer services, and other corporate events.
The filings identify DMIIU units, ordinary shares under DMII and rights under DMIIR on Nasdaq, and describe the company's emerging growth company status. For this SPAC, regulatory disclosures focus on unit and rights mechanics, shareholder-vote matters, governance and capital actions tied to its business-combination purpose.
Drugs Made In America Acquisition II Corp. reported an insider transaction on a Form 4. Director Catherine Do acquired 100,000 ordinary shares on 09/26/2025 under transaction code J.
According to the footnote, the shares were acquired from the Issuer’s sponsor, Drugs Made In America Acquisition II LLC, for no consideration. Following the transaction, the reporting person beneficially owned 100,000 shares held in direct ownership.